Document is current
Any future updates will be listed below
-
Authors
Alvarado-Villacorta, Rosa https://orcid.org/0000-0003-1885-2335
Merayo-Lloves, Jesús https://orcid.org/0000-0003-3740-3754
Sánchez-Ávila, Ronald M. https://orcid.org/0000-0002-5884-6741
Alfonso-Bartolozzi, Belén https://orcid.org/0000-0002-3151-0201
Lisa, Carlos https://orcid.org/0000-0003-4600-427X
Fernández-Vega-Cueto, Luis https://orcid.org/0000-0001-9197-5847
Alfonso, José F. https://orcid.org/0000-0002-0373-8209
Anitua, Eduardo https://orcid.org/0000-0002-8386-5303
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (RD21/0002/0041)
- License Information
-
More Information
Article History
Received: 10 May 2025
Accepted: 11 July 2025
First Online: 25 July 2025
Declarations
:
: The authors declare that Eduardo Anitua is the Scientific Director, and Ronald M. Sánchez-Ávila is a scientist at BTI Biotechnology Institute, a biomedical company that investigates the fields of regenerative medicine and PRGF-Endoret Technology. The other authors declare no conflicts of interest in developing this study.
: The protocol was approved by the Ethics Committees for Investigation with Medicinal Products of the Principality of Asturias (CEImPA 2023.281), and the procedures were conducted in adherence with the tenets of the Declaration of Helsinki. Written informed consents were obtained from every patient and donor before the procedure as routine clinical practice, including permission to use their medical records for scientific purposes. Authorization was granted by the Spanish Agency for Medicines and Health Products (AEMPS) to initiate allogeneic is-ePRGF as compassionate treatment for every enrolled patient.
